文献速递临床免疫分子诊断

HCV双抗体/抗原免疫测定与标准流程检测的比较

Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.
PubMed 文献 · J Clin Microbiol · 2024-09-16

本研究评估HCV Duo抗体/抗原联合免疫测定作为传统筛查替代方案的效用,对1,341例患者残留标本进行检测并与第三代血清学及核酸扩增检测比较。结果显示HCV Duo Ab+/Ag+标本中99.0%准确识别活动性感染,Ab-/Ag-标本中99.9%对应无感染,Ab/Ag检测可缩短诊断窗口但不能完全替代NAAT。

要点

  • HCV Duo Ab+/Ag+对活动性感染的阳性预测值高,99.0%与NAAT确认一致。
  • Ab/Ag联合检测可检出部分Ab-/RNA+病例,传统流程可能漏诊。
  • HCV Duo不能完全替代NAAT,部分患者仍需分子检测确认。

核心结论

  • 第四代HCV Duo Ab/Ag测定性能与标准流程相当,可缩短诊断窗口,但不能消除所有患者对NAAT的需求。
  • Ab/Ag检测可识别部分被当前标准流程漏诊的Ab-/RNA+病例,有望提高诊断效率与准确性。

研究设计与样本

  • 研究使用1,341例患者的残留标本,同时进行第三代血清学(Roche anti-HCV-II)和核酸扩增检测(NAAT)。
  • 所有标本使用HCV Duo Ab/Ag免疫测定(Roche)评估,并记录患者人口学、风险因素和标准流程实验室结果。

主要发现

  • HCV Duo Ab+/Ag+标本中99.0%(197/199)经NAAT确认准确识别活动性感染,Ab-/Ag-标本中99.9%(670/671)对应无HCV感染。
  • HCV Duo Ab组分与标准抗-HCV II Ab assay相比,阳性符合率(PPA)为95.6%(95% CI=93.8-96.9),阴性符合率(NPA)为99.1%(98.8-99.6)。
  • HCV Duo Ag与NAAT相比,PPA为73.5%(67.9-78.4),NPA为99.8%(99.3-100)。
  • RNA+标本中73.4%(197/267)为HCV Duo Ag+,265/267(99.3%)被HCV Duo Ab组分成功检出。
  • Ab-/RNA+标本中5/7(71.4%)被HCV Duo检出,这些病例传统算法检测可能漏诊。

临床怎么用

  • HCV Duo Ab/Ag联合检测可作为传统HCV筛查的替代方案,缩短诊断窗口,便于单次就诊干预和治疗。
  • 对于Ab/Ag检测阳性者,仍需根据临床情况决定是否进行NAAT确认,尤其不能完全替代分子检测。

局限性

  • 研究使用残留标本,可能受标本保存条件影响。
  • HCV Duo Ag组分PPA相对较低(73.5%),可能漏检部分RNA+病例。
  • 研究未报告成本效益及在资源有限地区的实施可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Centers for Disease Control and Prevention (CDC) guidelines for hepatitis C virus (HCV) testing, although effective, may miss crucial diagnostic opportunities. The goal of this study was to assess the utility of an antibody (Ab) and antigen (Ag) combination immunoassay as an alternative to traditional HCV screening. Remnant specimens from 1,341 patients with concurrent third-generation serologic (Roche anti-HCV-II) and nucleic acid amplification testing (NAAT) were assessed using the HCV Duo Ab/Ag immunoassay (Roche). Patient demographics, risk factors, and standard of care (SOC) laboratory results from the medical records were recorded. Overall, 99.0% (197/199) of the HCV Duo Ab+/Ag+specimens accurately identified active infections as confirmed by NAAT, and 99.9% (670/671) Ab-/Ag- samples corresponded to those without HCV infections. Individually, the HCV Duo Ab component demonstrated a 95.6% positive percent agreement (PPA) (95% CI = 93.8-96.9) and 99.1% negative percent agreement (NPA) (98.8-99.6) compared with SOC anti-HCV II Ab assay. The HCV Duo Ag had a 73.5% PPA (67.9-78.4) and 99.8% NPA (99.3-100) with NAAT. Among RNA+ specimens, 73.4% (197/267) were HCV Duo Ag+, and 265/267 (99.3%) were successfully detected on the HCV Duo Ab component. Notably, 5/7 (71.4%) Ab-/RNA +specimens were detected by HCV Duo, which would have been missed by traditional algorithmic testing. Fourth generation HCV Duo Ab/Ag assay demonstrated comparable performance to SOC testing and shortens the diagnostic window but does not eliminate the need for NAAT in all patients. Ab/Ag testing identified several Ab-/RNA+ cases, a subgroup often undiagnosed by current algorithmic testing, demonstrating promise for improved diagnostic efficiency and accuracy in HCV detection.IMPORTANCEThis study highlights the potential of a combined hepatitis C virus (HCV) Duo antibody (Ab) and antigen (Ag) immunoassay to improve early detection of HCV infections. Traditional Ab-only screening methods recommended by the Centers for Disease Control and Prevention may miss early-stage infections. The HCV Duo assay showed high accuracy, detecting nearly all active infections confirmed by nucleic acid amplification testing. Dual detection of HCV Ab and Ag shortens the diagnostic window, enabling intervention and treatment in a single visit, which is crucial for improving patient outcomes and reducing HCV transmission, especially in areas with limited access to confirmatory molecular testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bui TI, Brown AP, Brown M, et al. Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing. J Clin Microbiol. 2024. PMID: 39283072. doi:10.1128/jcm.00832-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。